ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Cytomegalovirus Infection and Disease in Pediatric Liver Transplantation: Burden of Disease Under a Preemptive Therapy Approach

J. Arroyo-Orvañanos, J. A. Hernández-Plata, R. Erro-Aboytia, J. Nieto-Zermeño, A. Reyes-López, G. Varela-Fascinetto

Transplant Department, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico

Meeting: 2020 American Transplant Congress

Abstract number: 586

Keywords: Cytomeglovirus, Liver transplantation, Pediatric

Session Information

Session Name: Liver: Pediatrics

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:03pm-4:15pm

Location: Virtual

*Purpose: To report the incidence cytomegalovirus (CMV) infection (CMV-I) and disease (CMV-D) in a cohort of pediatric liver transplant recipients under preemptive therapy, identify risk factors for CMV-I/D, analyze CMV related complications and document adverse reactions to antiviral treatment.

*Methods: All pediatric liver transplant recipients from a single center (1998-2018) were included. Antigenemia pp65 (AgPP65) was used from 1998-2003 and Nucleic Acid Amplification Test (NAT) starting in 2003, to inform preemptive therapy. These tests were conducted every 15 days for the first 6 months, then monthly for 6 months and afterwards every 3 months. CMV-I was defined as evidence of any viral replication and CMV-D as evidence of viral replication with symptoms or tissue invasive disease. The cut-off value for starting treatment was AgPP65>10 cells/200,000 or NAT>1500 copies/ml or any value in high-risk recipients (D+/R-). Initially, IV ganciclovir and more recently PO valganciclovir or a combination of both were used.

*Results: 118 pediatric liver transplant recipients were included, 63% were toddlers or preschool children, 24% were D+/R-, and the most common indication was Biliary Atresia (35%). CMV-I was detected in 67% of the patients, most of them were asymptomatic or self-limited, and only 38% reached the threshold for treatment. Only 5 patients (4%) developed CMV-D (3 viral syndromes and 2 hepatitis), in 2 of them the donor was CMV-IgM+ at the time of transplantation. All patients responded well to treatment and no graft or patient were lost to CMV. There were no differences in mortality, CMV indirect effects or other complications between those who required treatment and those who did not. Thirty one percent of the patients who received treatment, developed an adverse hematological reaction (thrombocytopenia 24%, anemia 13%, leucopenia 11%, neutropenia 2%) and 6 developed a subsequent episode of viral replication that responded well to a second course of treatment. Risk factors associated with CMV-I requiring treatment were: D+/R- (OR 13.9 p=0.01), fulminant hepatitis (OR 4.8 p=0.02) and thymoglobulin (OR 7 p=0.08).

*Conclusions: Preemptive therapy for CMV in children is safe and effective, yields low rates of CMV-I that requires treatment and low rates of CMV-D, without increasing CMV-related complications. By using this strategy, 62% of our patients did not receive treatment and therefore; drug exposure, costs, adverse reactions and the risk of resistance were minimized.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Arroyo-Orvañanos J, Hernández-Plata JA, Erro-Aboytia R, Nieto-Zermeño J, Reyes-López A, Varela-Fascinetto G. Cytomegalovirus Infection and Disease in Pediatric Liver Transplantation: Burden of Disease Under a Preemptive Therapy Approach [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/cytomegalovirus-infection-and-disease-in-pediatric-liver-transplantation-burden-of-disease-under-a-preemptive-therapy-approach/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences